Elotuzumab, a humanized IgG1 mAb that targets SLAMF7 via ADCC and FcγRIIIA engagement (CD16) on NK cells, is approved in combination with dexamethasone and lenalidomide or pomalidomide for MM treatment [109]. This evidence concerns the gene FCGR3A and Miyoshi myopathy.